DEXCOM INC

DexCom Q2 Earnings Beat Expectations, Analyst Upgrades Boost Stock Outlook

DexCom’s Q2 earnings beat expectations, boosting analyst ratings and price targets as the CGM market expands beyond insulin users.

Newsredaktion

01/08/2026, 23:30

3 minutes to read

Dexcom Q3 Surge: 20% Growth, Record Earnings, but Stock Drops Amid Cautious Outlook

Dexcom Inc. reports a 20% Q3 earnings surge amid cautious outlook, stock dip, and class‑action lawsuit—what this means for investors and the CGM market.

Samantha Roth

31/10/2025, 16:10

3 minutes to read

Dexcom’s Q3 Earnings Beat, Yet Stock Slumps Amid Investor‑Litigation Concerns

Dexcom Inc. balances strong Q3 earnings with a class-action lawsuit over device reliability, prompting investor caution despite board expansion and a $94 price target.

Jake Connors

30/10/2025, 22:30

3 minutes to read

Dexcom Inc. Faces Stock Decline Amid Leadership Changes and Market Scrutiny

Dexcom Inc., a leading medical device company, has experienced a significant drop in its stock price due to a combination of internal challenges, including leadership changes and a short report on its G7 device, and external market developments, but…

Samantha Roth

19/09/2025, 19:00

3 minutes to read